Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
CAMBRIDGE, Mass., March 01, 2017 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27th Annual Healthcare Conference.
Details of the upcoming presentations are as follows:
Wednesday, March 8th
Cowen and Company 37th Annual Health Care Conference
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: Boston, Massachusetts
Presentation Time: 8:40 am ET
Wednesday, March 15th
The Goldman Sachs Third Annual Innovation Symposium
Gene Editing and CRISPR Panel
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: New York, New York
Panel Time: 10:15 am ET
Wednesday, March 22nd
The Oppenheimer 27th Annual Healthcare Conference
Who: John Leonard, M.D., executive vice president, R&D
Location: New York, New York
Presentation Time: 2:45 pm ET
Individuals may access the presentations for available conferences via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. When available, replays of these webcasts will be available on the site for 90 days following the live events.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Senior Vice President, External Affairs & Communications +1 (857) 706-1071 [email protected] Investor Contact: Graeme Bell Chief Financial Officer +1 (857) 706-1081 [email protected]
